All News

FDA clearance of the IND for UGN-501 paves the way for a first-in-human phase 1 trial evaluating its safety and feasibility in patients with NMIBC.

The findings suggest that a significant proportion of participants may benefit from discontinuing tamsulosin.

Sender Herschorn, BSc, MDCM, FRCSC, discusses a subgroup analysis of the COURAGE trial showing that vibegron provided comparable efficacy and favorable safety in men aged 75 years and older with persistent OAB symptoms receiving pharmacotherapy for BPH.

In this episode, Anup A. Vora, MD, discusses patient selection for focal therapy in localized prostate cancer, the role of precision medicine, and how advanced practice providers are helping deliver comprehensive, patient-centered GU oncology care.

Urocross produced deepening IPSS improvement through 24 months post-retrieval, with Kevin T. McVary, MD, FACS, attributing a post-removal symptomatic boost to completed prostatic remodeling and full preservation of future treatment options.

A recent meta-analysis suggests that the Prolaris combined clinical risk score is prognostic across NCCN risk groups in men with localized prostate cancer.

Amy Pearlman, MD, and guests discuss how to address unmet needs in bladder care through telehealth, education, and behavioral interventions.

Kristen Scarpato, MD, discusses 2026 AUA/SUO Advanced Prostate Cancer Guideline amendment recommendations on the use of PSMA-PET imaging for staging and treatment selection.

Data from the ARC-20 study are the first to link HIF-2a inhibitor-associated changes in circulating serum EPO, tumor biology, and clinical activity.

Matthew Truesdale, MD, FACS, discusses validation data showing that IsoPSA improves risk stratification for clinically significant prostate cancer in men with elevated PSA both with and without pre-biopsy mpMRI.

"This is really going to make access to care a lot better, and workflow is going to be a lot easier," says Ben H. Chew, MD, MSc, FRCSC.

In this episode of The UroOnc Minute, host Adam Weiner, MD, is joined by David Canes, MD, for a thoughtful discussion on practical strategies to improve efficiency, reduce physician burnout, and preserve meaningful patient-centered care in urologic oncology.

These results are intended to support a premarket approval submission for an expanded indication of the Vanquish device for the management of clinically localized prostate cancer.

Enucleation is appropriate for the vast majority of patients with BPH, but certain patient profiles—including prior radiation, significant neurologic conditions, morbid obesity, and dementia—warrant caution or referral to specialists, whereas the most consistent technical failure among surgeons past their learning curve is inadequate apical tissue removal driven by discomfort with sphincter proximity, according to Amy E. Krambeck, MD.

Gopa Iyer, MD, reviews early NEXUS-01 data evaluating the investigational anti–Nectin-4 ADC LY4052031, highlighting the importance of CYP2D6-guided dosing to optimize safety.

A recap of the FDA submissions and regulatory decisions in urology from June 2026.

A health-economic analysis of the ASPIRE trial data found that the steerable ureteroscopic renal evacuation (SURE) procedure was linked to roughly $3464 in downstream savings per patient over 2 years compared with standard ureteroscopy, with lead investigator Brett Johnson, MD, framing this as a value-committee benchmark rather than a full cost comparison, since the analysis deliberately excludes the index procedure's incremental cost due to wide variability across payers and care settings.

In this episode, host Amy Pearlman, MD, is joined by Larry Lipshultz, MD, and Nicholas Deebel, MD, to discuss a new men's health program and a clinical trial evaluating incobotulinumtoxinA for erectile dysfunction.

A roundup of the key stories on benign urologic conditions from the second quarter of 2026.

A roundup of the key stories across genitourinary cancers from the second quarter of 2026.

The FDA's proposed narrowing of the testosterone therapy prostate cancer contraindication to metastatic disease only reflects current clinical evidence, opening the door to testosterone therapy in appropriately selected men with treated localized prostate cancer or on active surveillance, with shared decision-making and PSA-testosterone co-monitoring as the foundation of responsible care, as Helen L. Bernie, DO, MPH, outlines in this interview.

"Ultimately, integrating robust, disease-specific PROs into routine bladder cancer care represents a key step toward more truly patient-centered management," write the authors.

Interim results from the phase 2 CONVERGE-01 trial showed encouraging antitumor activity and a manageable safety profile with Ac-225 rosopatamab tetraxetan in mCRPC.

Sanoj Punnen, MD, highlights the importance of assessing and managing cardiovascular risk when initiating androgen deprivation therapy for patients with prostate cancer.

Atish D. Choudhury, MD, PhD, discusses findings from the A-DREAM / Alliance A032101 trial evaluating treatment interruption following favorable response to combination ADT and ARPI therapy in mHSPC.

The tentative approval spans tablets in 40-mg, 80-mg, 120-mg, and 160-mg strengths.

In this episode of The UroOnc Minute, Adam B. Weiner, MD, is joined by Keyan Salari, MD, PhD, to examine the results of the PROTEUS trial and their implications for managing high-risk localized prostate cancer.

Kevin Koo, MD, MPH, highlights findings from a study evaluating automated kidney stone detection and measurement on CT.